Mentari Therapeutics, Inc. Common Stock
MTRI
4 hedge funds and large institutions have $28.5K invested in Mentari Therapeutics, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
0.11% less ownership
Funds ownership: 0.53% → 0.42% (-0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$4.57K |
| 2 |
Tower Research Capital (TRC)
New York
|
+$1.11K |
Top Sellers
MTRI Hedge Fund Activity: Q2 2025 in Review
4 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in Mentari Therapeutics, Inc. Common Stock (MTRI) for Q2 2025, worth a combined $28.5K — up 115% from $13.3K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new MTRI positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $4.57K.
- 4 institutional investors held Mentari Therapeutics, Inc. Common Stock (MTRI) as of Q2 2025, up from 3 in Q1 2025.
- Funds reported $28.5K of Mentari Therapeutics, Inc. Common Stock stock for Q2 2025, up 115% quarter-over-quarter.
- 1 fund opened new Mentari Therapeutics, Inc. Common Stock positions in Q2 2025 and 0 closed out, a net change of +1 holder.
- The largest Mentari Therapeutics, Inc. Common Stock buyer in Q2 2025 was UBS Group, an estimated $4.57K added.
Based on aggregated 13F filings for Q2 2025.